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Abstract 
Introduction: Interest on the impact of variant histology in bladder cancer prognosis is 
increasing. Although squamous differentiation (SQD) is the most well characterized, only 
recently have less common variants gained increased recognition. We assessed 
whether SQD conferred worse prognosis than non−variant (NV) urothelial bladder 
cancer in a contemporary cohort of radical cystectomy patients given the increased 
awareness of other less common variants.  
Methods: We identified patients with SQD or NV histology on TURBT and/or cystectomy 
pathology over a ten-year period.  Disease-specific and overall survival were evaluated 
using Kaplan−Meier methodology. Cox regression assessed variables associated with 
mortality.  
Results: Between 2003 and 2013, 934 patients underwent cystectomy for urothelial 
bladder cancer. 617 NV and 118 SQD patients were identified. The remainder were non-
SQD variant histology patients. 75% of SQD had muscle invasive disease at diagnosis 
compared with 59% of NV (p=0.002). Non−organ confined disease at cystectomy was 
more common in SQD (57% vs. 44%, p=0.009). Among patients receiving neoadjuvant 
chemotherapy, 20% (9/45) of NV and 13% (1/8) of SQD patients were pT0N0 (p=0.527). 
Median follow−up was 52 months. Adjusted for demographics, pathologic stage, and 
chemotherapy, SQD was not associated with increased risk of disease specific (HR 
1.35, 95%CI 0.90-2.04, p=0.150) or all−cause mortality (HR 0.90, 95%CI 0.60−1.25, 
p=0.515).  
Conclusions: In a contemporary cohort of urothelial bladder with recognition and 
characterization of less commonly described variants, SQD is not associated with a 
worse disease specific and all-cause mortality when compared to a pure NV cohort.  
 
 
Introduction 
While variant histology within urothelial bladder cancer has been documented for 
decades, the World Health Organization (WHO) did not include variant histology in 
bladder cancer classifications until 2004, and the clinical significance of variant bladder 
cancer has yet to be fully determined 1, 2. Collectively, variant histology is often 
associated with more advanced disease and worse survival 3-6. Nonetheless, the 
heterogeneity of urothelial bladder cancer and the ability to display clinicopathologic 
characteristics of single or multiple variant subtypes has complicated the understanding 
of variant tumor biology even further.  
As one of the first classified variants, squamous differentiation (SQD) has 
consistently been described as the most common variant subtype, comprising anywhere 
between 30-80% of variant bladder cancers 2, 3, 6-10. Although SQD was previously shown 
to be associated with higher pathologic staging and increased risk of local recurrence, 
when accounting for stage, SQD does not alter overall survival (OS) or disease-specific 
survival (DSS) 7, 8, 11-13. Furthermore, there is evidence suggesting that SQD may be 
equally sensitive to chemotherapy as non-variant (NV) urothelial bladder cancer 10, 12, 14-
17.  
Although SQD and NV seem to act similarly, many of the previous studies on 
SQD derive from older cohorts of patients, prior to the 2004 WHO classifications1. Since 
use of systemic chemotherapy has increased, peri-operative care and surgical 
techniques have improved, and awareness of less commonly described variants has 
increased, we sought to assess whether SQD confers worse prognosis than NV 
urothelial cancer in a contemporary series of patients undergoing radical cystectomy. 
 
 
 
Materials and Methods 
Population 
Institutional Review Board approval was granted for the conduct of this study.  
We conducted a retrospective cohort analysis of our Institutional Bladder Cancer 
Database to identify all patients with urothelial carcinoma undergoing radical cystectomy 
with curative intent between 2003 and 2013 (n=934).  Patients with non-urothelial cancer 
on transurethral resection of bladder tumor (TURBT) or cystectomy pathology were not 
included in this cohort.  As the primary focus of this project was comparison of SQD with 
NV patients, patients with other variant histology on either TURBT or cystectomy 
(n=199) were excluded. SQD variant status was assigned by central pathologic review. 
A single dedicated genito-urinary pathologist reviewed all cases. All outside TURBT 
specimens were also re-reviewed by the genito-urinary pathologist. In the setting of 
unclear pathology, slides were reviewed with other dedicated genito-urinary pathologists 
in the department to determine appropriate assignment of variant status. Any component 
of SQD variant histology with primary urothelial bladder cancer was considered sufficient 
to be identified as SQD for the purposes of this study.        
Outcomes and variables 
The primary outcomes of interest in this study were non-organ confined disease 
at the time of radical cystectomy, disease specific survival (DSS), and overall survival 
(OS).  These were thought to represent both short and long term oncologic outcomes.  
Non-organ confined disease was defined as ≥pT3 or lymph node (LN) involvement.  OS 
and DSS were assessed using our Institutional Cancer Registry and electronic medical 
records. 
Variables included in the analyses were demographic, TURBT related, 
cystectomy related, and therapy related.  Demographic variables were age, sex, and 
race. TURBT related included lymphovascular invasion, carcinoma in situ (CIS), TURBT 
stage, and grade. Cystectomy related variables included pathologic stage, grade, 
surgical margin status, CIS, and LN positivity and density. LN density was calculated as 
the number of positive LN divided by the total number of LN removed in patients with 
positive LN disease.  Therapy related variables included neoadjuvant chemotherapy and 
post-operative chemotherapy. 
Statistical analyses 
Descriptive analysis was performed using Pearson’s chi-squared test, Student’s 
t-test, Fishers exact test, and the Mann-Whitney U-test as appropriate to the data.  In the 
setting of non-normally distributed data, the median with interquartile range (IQR) are 
presented.  Kaplan-Meier methodology with log-rank test was used to evaluate DSS and 
OS for SQD and NV patients.  Cox proportional hazards regression models were 
generated to evaluate the relationship between SQD and both disease specific and all-
cause mortality.  These models were adjusted for age, sex, systemic chemotherapy, 
pathologic stage, and LN status.  Variables chosen for inclusion in the models were 
decided upon a priori as variables considered to have the potential to confound the 
relationship between SQD variant histology and survival.  A priori significance was set at 
p<0.05 for two-tailed tests.  All statistical analyses were performed using Stata 12.1 
(Stata Corp. LP, College Station, TX).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
Among the patients who underwent radical cystectomy, 735 patients met 
inclusion criteria. Six hundred and seventeen (83.9%) tumors displayed NV histology 
while the remaining 118 patients had SQD (16.1%). Twenty-six patients had SQD 
identified exclusively on TURBT, forty-two had SQD exclusively on cystectomy, and 
forty-three had SQD identified on both TURBT and cystectomy specimens. SQD patients 
made up 37% (118/317) of variant bladder cancer patients. SQD patients were older 
than NV patients (68.5 vs 66.1 years, p=0.033) and a greater proportion were female 
(31% vs 20%, p=0.009). On TURBT a higher proportion of SQD patients had evidence of 
muscle invasion (75% vs 59%, p=0.002) although incidence of LVI and CIS were similar 
between cohorts (Table 1). 
SQD patients had higher pathologic staging (p=0.001). Although SQD patients 
had higher incidence of non-organ confined disease (57% vs 44%, p=0.009), there was 
no significant difference in the proportion of patients with positive surgical margins or 
positive LN (Table 2). A higher proportion of NV patients were identified as having CIS 
on cystectomy pathology (57% vs 44%, p=0.038). NV and SQD patients received 
systemic chemotherapy comparably (23% vs 24%, p=0.836) (Table 2).  
Median follow-up for the cohort was 52 (range: 30-83) months. Although SQD 
and NV patients had similar OS, SQD patients had worse DSS (p=0.049) (Figure 1a,b). 
SQD and NV patients had similar OS and DSS when compared based on organ-
confined disease at time of cystectomy or muscle invasion at TURBT (Figure 2a,b; 
Figure 3a,b). Univariate analysis found increasing age, increasing pathologic stage and 
lymph node status were associated with increased mortality (Appendix 1). Use of 
Systemic chemotherapy was associated with all-cause mortality (Appendix 1). After 
controlling for demographics, systemic therapy use, and pathologic staging, SQD did not 
portend an increased risk of disease specific (HR=1.35; 95%CI 0.90-2.04; p=0.150) or 
all-cause mortality (HR=0.90; 95%CI 0.65-1.25; p=0.515) (Table 3). Increasing 
pathologic stage and positive lymph nodes were the only factors associated with 
increased risk of disease-specific and all-cause mortality (Table 3).  
Discussion 
 Understanding the clinical significance of variant histology, when combined with 
other clincopathologic factors, may improve the ability to individualize treatment and 
counseling of patients. While recent studies have found certain variants such as 
micropapillary and plasmacytoid to act more aggressively, SQD has been historically 
described to act similarly to NV histology 5, 11, 14, 15, 18, 19. However, much of the SQD 
literature draws on older cohorts. These reports may have missed less common variants 
such as micropapillary, plasmacytoid, and sacromatioid and grouped these patients 
within the NV or SQD groups. Recently, Linder et al demonstrated that re-review of 
urothelial carcinoma pathology by a dedicated urologic pathologist found that one of 
every three variant histology tumors was misinterpreted as NV urothelial carcinoma 3. 
Furthermore, Shah et al found that variant histology in community practice is under-
recognized in 44% of cases 20. Therefore, we provide an analysis of our experience with 
SQD and NV urothelial carcinoma among a well-defined, contemporary cohort of 
patients, whose variant histology has been assigned through a centralized pathologic 
review process. 
 While much has been published on SQD, the true prevalence of SQD tumors is 
unknown. As the earliest documented variant, older cohorts found SQD tumors to 
comprise upwards of 80% of variant bladder cancers 2, 21, 22. However more recent 
studies have demonstrated SQD to make up a lower proportion of variant bladder 
cancers 6, 7. Our cohort of patients demonstrated that the proportion of variant bladder 
cancer with SQD was closer to the lower limits of what has previously been reported, 
approximately 37% (118/317). These findings provide a more accurate depiction of the 
SQD population and are likely a result of our centralized pathologic review process 
coupled with an increased awareness towards non-SQD variants. 
 Reports prior to the 2004 WHO guideline inclusion of variant histology in 
pathologic reporting found that patients with SQD presented at a higher clinical stage 6, 9. 
Billis et al assessed 165 TURBT specimens regardless of treatment and demonstrated 
SQD to be muscle invasive in 75% of the patients while NV tumors demonstrated 
invasion in 22.2% 9. Wasco et al found the difference in muscle invasive disease on 
TURBT to be less dramatic but still significant in a cohort of radical cystectomy patients 
6. They reported 85.7% of SQD patients and 52.3% of NV patients having muscle 
invasive disease. Our study is consistent with the prior reports with 75% of SQD and 
59% of NV patients having muscle invasion. While the difference in muscle invasion 
between SQD and NV tumors is more drastic when looking at all TURBT specimens, 
even in cohorts of only radical cystectomy patients, SQD tumors demonstrates muscle 
invasion more often. 
 Consistent with the TURBT findings, SQD have historically been known to have 
more advanced pathologic disease 7, 8, 23. Kim et al found that variant tumors had almost 
double the incidence of non-organ confined disease as well as increased LN 
involvement 7. These findings were corroborated by Xylinas et al that also demonstrated 
more advanced pathologic staging and LN involvement in SQD patients 23. We too 
demonstrate more advanced pathologic staging in our SQD patients, but we found no 
significant difference in LN status at the time of radical cystectomy.  
While there is relatively limited literature addressing chemotherapy response in 
variant bladder cancer, SQD has been previously shown to be equally chemosensitive 
as NV urothelial carcinoma 12, 14-16. Logothetis et al published two retrospective studies 
using CISCA (cisplatin, cyclophosphamide, and doxorubicin) for adjuvant treatment or 
salvage therapy in SQD patients. Both studies reported SQD to have similar responses 
to chemotherapy compared to the NV group. Similarly, Kastritis et al found that when 
treating advanced or metastatic urothelial carcinoma with a platinum-based 
chemotherapy regimen, SQD and NV bladder cancer exhibited similar responsiveness 
16. Lastly, in a secondary analysis of the SWOG S8710 clinical trial using neoadjuvant 
MVAC (methotrexate, vincristine, doxorubicin, and cisplatin), SQD demonstrated non-
statistically significant (p=0.09) improved survival benefit compared to NV in locally 
advanced urothelial carcinoma 14. In our cohort, patients receiving neoadjuvant 
chemotherapy responded at similar rates although we are significantly underpowered to 
fully evaluate this. Although systemic chemotherapy was not associated with OS or DSS 
on multivariate analysis, we likely are underpowered to determine a difference.  
When comparing unadjusted DSS in SQD and NV patients, SQD patients did 
worse. However, after grouping patients based on muscle invasion on TURBT, the 
difference no longer exists. This finding remains consistent when comparing based on 
organ and non-organ confined disease on post-cystectomy pathology. Furthermore, on 
Cox proportional hazards regression, only pathologic staging and LN status were 
associated with increased risk of disease specific and all-cause mortality. Our findings 
are consistent with previously reported studies that have shown that SQD does not 
portend worse survival on multivariate analysis 6, 7, 11, 23.  
There are limitations to our study that warrant discussion. Our study is a 
retrospective review of urothelial carcinoma patients operated on by multiple surgeons at 
a single, high volume tertiary center. Therefore, both the surgical technique as well as 
the patient population may not be generalizable to all practices. A recent report 
demonstrated that extent of SQD was associated with worse survival by univariate 
analysis, but lost significance under multivariate analysis. 24 Unfortunately, we are 
unable to evaluate the impact that extent of SQD has on clinicopathologic outcomes, 
which is an important next step in research on variant histology. Finally, as only a small 
proportion of patients underwent neoadjuvant chemotherapy, it is inappropriate to draw 
conclusions regarding response to chemotherapy from our cohort of patients.  
Nevertheless, given these limitations, we believe our analysis bolsters the understanding 
of SQD in relation to NV urothelial carcinoma. Despite more advanced disease at 
presentation and final pathology, DS and all-cause mortality may be similar between 
SQD and NV.  
 
 
Conclusions 
 We found that SQD represents a smaller proportion of variant urothelial bladder 
cancers than what had previously been reported likely as a result of increased 
awareness towards non-SQD histology within urothelial bladder cancer. Although SQD 
patients present at an advanced stage, the histologic variant itself does not signify worse 
survival. These findings may have important implications on the management and 
counseling of SQD patients after TURBT and cystectomy. Further understanding SQD 
response to radiation and chemotherapy should be an important consideration for future 
studies, but there is significant evidence to suggest SQD is equally chemosensitive. 
Given our current knowledge of SQD histology, counseling and treating SQD patients 
similar to NV patients would seem appropriate. 
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Figure 3. Disease specific survival based on cystectomy (A) and TURBT (B) 
pathology of squamous differentiation and non-variant organ patients. 
 
 
NV organ confined vs. SQD organ confined, p=0.2528 
NV non-organ confined vs. SQD non-organ confined, p=0.0732 
 
NV TURBT non-muscle invasive vs. SQD non-muscle invasive, p=0.9041 
NV TURBT muscle invasive vs. SQD muscle invasive, p=0.2570  
